PROLIA (DENOSUMAB): REVIEW OF THE LATEST PUBLICATIONS OF AMERICAN SOCIETY OF BONE AND MINERAL RESEARCH (ASMBR) IN 2014

1. Adachi J.D., Ho P.R., Lin C.J.F., Bolognese M.A., Bone H.G., Hadji P., Papapoulos S., Recknor C., Daizadeh N.S., Dakin P., Wagman R.B., Ferrari S. Evolution of Subject Characteristics in FREEDOM and its Extension for Up to 8 Years. J Bone and Mineral Research; 29 (Supple 1): MO0391.

2. Cummings S.R., Vittinghoff E., Daizadeh N.S., Austin M., Wang A., Wagman R.B. Virtual Twin Estimates: Continued New Vertebral and Nonvertebral Anti-Fracture Efficacy Through 8 Years of Treatment With Denosumab. J Bone and Mineral Research; 29 (Supple 1): FR0397.

3. Ferrari S., Libanati C., Lin. C.J.F., Adami S., Brown J.P., Cosman F., Czerwinski C., de Grego rio L.H., Malouf J., Reginster J.-Y., Daizadeh N.S., Wang A., Wagman R.B., Lewiecki E.M., Cummings S. Percentage of Women Achieving Non-osteoporotic BMD T-scores at the Spine and Hip Over 8 Years of Denosumab Treatment. J Bone and Mineral Research; 29 (Supple 1): SA0391.

4. Bilezikian J.P., Benhamou C.L., Lin C.J.F., Brown J.P., Daizadeh N.S., Ebeling P.R. Fahrleitner-Pammer A., Franek E., Gilchrist N., Miller P.D., Simon J.A., Valter I., Zerbini C.A.F., Libanati C. Denosumab Restores Cortical Bone Loss at the Distal Radius Associated With Aging and Reduces Wrist Fracture Risk: Analyses From the FREEDOM Extension Cross-over Group. ASBMR 2014 oral presentation.

5. Napoli N., Vittinghoff E., Pannacciulli N., Crittenden D., Yun J., Wang A., Wagman R., Schwartz A. Effect of Denosumab on Fasting Glucose Concentrations in Postmenopausal Women with Osteoporosis: Results From Subjects With Diabetes or Prediabetes From the FREEDOM Trial. ASBMR 2014 oral presentation.

6. Watts N.B., Grbic J.T., McClung M., Papapoulos S., Kendler D., Teglbjaerg C.S., O’Connor L., Wagman R.B., Ng E., Daizadeh N.S., Ho P.R. Evaluation of Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab: Results From the Pivotal Phase 3 Fracture Study Extension. J Bone and Mineral Research; 29 (Supple 1): SA0387.

7. Geller M., Wagman R.B., Ho P.R., Siddhanti S., Stehman-Breen C., Watts N.B., Papapoulos S. Findings from Denosumab (Prolia) Post-marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis. J Bone and Mineral Research; 29 (Supple 1): SA0388